DGAP-News: Formycon AG / Key word(s): Change of Personnel/Miscellaneous Formycon AG: Formycon CEO Dr. Carsten Brockmeyer once again honored as one of the world's most influential people in the medicines industry 14.06.2016 / 07:30 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Press Release // June 14, 2016 Formycon CEO Dr. Carsten Brockmeyer once again honored as one of the world's most influential people in the medicines industry - Highly respected magazine "The Medicine Maker" lists the Formycon head for the second time in a row - Selection based on achievements in pharmaceutical development Munich - Dr. Carsten Brockmeyer, CEO of the biosimilar company Formycon AG, has again been chosen as one of the world's top 100 most influential people in the pharmaceutical sector by the trade magazine "The Medicine Maker". Brockmeyer was also included in the "Medicine Maker Power List" last year. Dr. Brockmeyer is joined on the list by other highly decorated people from the worlds of industry and science, including Nobel Prize winners, CEOs and a host of outstanding scientists from the pharmaceutical sector. "I'm delighted to once again have been included in this group of outstanding people in the medicines industry. It shows that biosimilars are constantly growing in importance in the world of medicine. This further accolade also bears testimony to the services that the entire Formycon team has been contributing for years," said Dr. Carsten Brockmeyer. The Medicine Maker is a trade magazine published in the United Kingdom and which read all over the world. The list is compiled from readers' nominations and assistance from experts and is based exclusively on services rendered to medicines development. The rankings are determined in three steps. First, the magazine's readers are asked which people from the pharmaceutical industry they would include on the list. Out of these nominees, the jurors each select their 100 most influential people. These lists are then consolidated into the final document. The list can be viewed at the following address: https://themedicinemaker.com/power-list/2016/ About Formycon: Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon's specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH. About biosimilars: Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis and multiple sclerosis. In the coming years, many of these biotech drugs will lose their patent protection - and by 2020, medications with revenues of more than USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. While the global market for biosimilars is currently some USD 2.5 billion, industry experts expect this figure to grow tenfold by the year 2020. In contrast to traditional generic drugs, the development and production of biosimilars is highly complex and requires specialized expertise. Contact: Thorsten Schüller Corporate Communications and Investor Relations Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg/Germany phone +49 (0) 89 - 86 46 67 150 fax + 49 (0) 89 - 86 46 67 110 [email protected] // www.formycon.com Disclaimer: This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety and patent litigation. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States. --------------------------------------------------------------------------- 14.06.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Formycon AG Fraunhoferstraße 15 82152 Planegg-Martinsried Germany Phone: 089 864667 100 Fax: 089 864667 110 Internet: www.formycon.com ISIN: DE000A1EWVY8 WKN: A1EWVY Listed: Regulated Unofficial Market in Berlin; Open Market (Entry Standard) in Frankfurt End of News DGAP News Service --------------------------------------------------------------------------- 471251 14.06.2016